These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26454353)

  • 1. Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
    Buysschaert B; Aydin S; Morelle J; Hermans MP; Jadoul M; Demoulin N
    Diabetes Metab; 2016 Feb; 42(1):62-4. PubMed ID: 26454353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.
    Kwan TK; Chadban SJ; McKenzie PR; Saunders JR
    Nephrology (Carlton); 2013 Mar; 18(3):241-2. PubMed ID: 23432752
    [No Abstract]   [Full Text] [Related]  

  • 3. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
    Solomon LR; Nixon AC; Ogden L; Nair B
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29133578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An unusual complication of treatment with orlistat.
    Karamadoukis L; Shivashankar GH; Ludeman L; Williams AJ
    Clin Nephrol; 2009 Apr; 71(4):430-2. PubMed ID: 19356376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.
    Dossabhoy NR; McRight S; Sangha B; Khan S; Adgeh C
    J La State Med Soc; 2013; 165(5):283-5. PubMed ID: 24350530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
    Singh A; Sarkar SR; Gaber LW; Perazella MA
    Am J Kidney Dis; 2007 Jan; 49(1):153-7. PubMed ID: 17185156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orlistat and calcium oxalate crystalluria: an association that needs consideration.
    Ahmed MH
    Ren Fail; 2010; 32(8):1019-21. PubMed ID: 20722574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat: Current issues for patients with type 2 diabetes.
    Mancino JM
    Curr Diab Rep; 2006 Nov; 6(5):389-94. PubMed ID: 17077001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?
    Karamadoukis L; Ludeman L; Williams AJ
    Nephrol Dial Transplant; 2008 May; 23(5):1778-9. PubMed ID: 18272781
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat: hepatitis and oxalate nephropathy.
    Prescrire Int; 2012 Mar; 21(125):71. PubMed ID: 22428191
    [No Abstract]   [Full Text] [Related]  

  • 13. Orlistat, an under-recognised cause of progressive renal impairment.
    Coutinho AK; Glancey GR
    Nephrol Dial Transplant; 2013 Nov; 28 Suppl 4():iv172-4. PubMed ID: 24049105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-risk assessment of orlistat in the treatment of obesity.
    Sumithran P; Proietto J
    Drug Saf; 2014 Aug; 37(8):597-608. PubMed ID: 25064699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on orlistat in the management of patients with obesity.
    Curran MP; Scott LJ
    Treat Endocrinol; 2005; 4(2):127-9. PubMed ID: 15783249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat-associated adverse effects and drug interactions: a critical review.
    Filippatos TD; Derdemezis CS; Gazi IF; Nakou ES; Mikhailidis DP; Elisaf MS
    Drug Saf; 2008; 31(1):53-65. PubMed ID: 18095746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.
    Garg R; Hussey C; Ibrahim S
    Diabet Med; 2010 Apr; 27(4):485-6. PubMed ID: 20536524
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxalate crystal-related acute renal injury caused by orlistat: A case report.
    Cui X; Chen X; Li Y; Fu X; Song P; Xiao L; Sun L; Liu H; Zhu X; Yuan S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):583-587. PubMed ID: 35753728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.